Rituximab: Modes of Action, Remaining Dispute and Future Perspective
Authors:
- 19 December 2014
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 10 (15) , 2481-2492
Abstract
Less than two decades ago, immunotherapy joined chemotherapy and radiotherapy as an effective approach for the treatment of cancer. The anti-CD20 monoclonal antibody, rituximab, is now used to treat almost all types of non-Hodgkin's B-cell lymphomas, and it could be useful in the treatment of other diseases with B-cell involvement. Upon binding, rituximab induces death of the target cells. It seems to act not only by activating immune system defense mechanisms such as complement-dependent and antibody-dependent cellular cytotoxicity, but also by inducing direct cell death. In this paper, we review current knowledge on rituximab mechanisms of action, with particular attention to its direct effects, and also highlight potential future avenues of research.Keywords
This publication has 90 references indexed in Scilit:
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patientsAnnals of the Rheumatic Diseases, 2013
- Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicityLeukemia, 2013
- Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximabAnnals of Hematology, 2013
- Rituximab resistanceBest Practice & Research Clinical Haematology, 2011
- Rituximab in Indolent LymphomasSeminars in Hematology, 2010
- Is complement good or bad for cancer patients? A new perspective on an old dilemmaTrends in Immunology, 2009
- The involvement of mitochondria and the caspase-9 activation pathway in rituximab-induced apoptosis in FL cellsApoptosis, 2009
- Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II StudyJournal of Clinical Oncology, 2008
- BAFF‐modulated repopulation of B lymphocytes in the blood and salivary glands of RITUXIMAB‐TREATED patients with Sjögren's syndromeArthritis & Rheumatism, 2007
- The epitope recognized by rituximabBlood, 2006